바로가기
본문 바로가기
메인메뉴 바로가기
HOME
CONTACT US
메인메뉴
Introduction
About Lab
Contact Us
Members
Professor
Member
Alumni
Research
Research
Publications
Translational Research
Clinical Research
Journal Club
Journal Club
Board
Notice
Link
Gallery
CGRL
Cancer Genomics
Research Laboratory
Publications
Translational Research
Clinical Research
Translational Research
Home > PUBLICATIONS > Translational Research
No.
Journal
File
27
Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY. , Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer., BRITISH JOURNAL OF CANCER, 2009 Jan 27;100(2):298-304
26
Kim SH, Park J, Choi MC, Park JH, Kim HP, Lee JH, Oh DY, Im SA, Bang YJ, Kim TY., DNA methyltransferase 3B acts as a co-repressor of the human polycomb protein hPc2 to repress fibroblast growth factor receptor 3 transcription, Int J Biochem Cell Biol 2008;40(11):2462-71.
25
Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY., The Clinicopathologic characteristics and prognostic significance of triple negativity in node-negative breast cancer, BMC CANCER, 2008 Oct 23;8:307
24
Han SW, Kim HP, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY., Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment, LUNG CANCER, 2008 Jul;61(1):30-4
23
Park JH, Kim SH, Choi MC, Lee J, Oh DY, Im SA, Bang YJ, Kim TY., Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008 Apr 4;368(2):318-22
22
Kim HP, Han SW, Kim SH, Im SA, Oh DY, Bang YJ, Kim TY., Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells, MOLECULAR CANCER THERAPEUTICS, 2008 Mar;7(3):607-15
21
Jung Y, Park J, Bang YJ, Kim TY., Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers, LABORATORY INVESTIGATION, 2008 Feb;88(2):153-60.
20
Park JH, Jong HS, Kim SG, Jung Y, Lee KW, Lee JH, Kim DK, Bang YJ, Kim TY., Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase, JOURNAL OF MOLECULAR MEDICINE-JMM 2008 Jan;86(1):117-28.
19
Kim TY, Han SW, Bang YJ., Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2007 Nov;7(6):821-36.
18
Jung Y, Park J, Kim TY, Park JH, Jong HS, Im SA, Robertson KD, Bang YJ, Kim TY., Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy, JOURNAL OF MOLECULAR MEDICINE-JMM, 2007 Oct;85(10):1137-48.
17
Han SW, Jeon YK, Lee KH, Keam B, Hwang PG, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY., Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer, PHARMACOGENETICS AND GENOMICS, 2007 May;17(5):313-9.
16
Kim SH, Park J, Choi MC, Kim HP, Park JH, Jung Y, Lee JH, Oh DY, Im SA, Bang YJ, Kim TY., Zinc-fingers and homeoboxes 1 (ZHX1) binds DNA methyltransferase (DNMT) 3B to enhance DNMT3B-mediated transcriptional repression, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007 Apr 6;355(2):318-23.
15
Lee JH, Park JH, Jung Y, Kim JH, Jong HS, Kim TY, Bang YJ., Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells, MOLECULAR CANCER THERAPEUTICS, 2006 Dec;5(12):3085-95.
14
Han SW, Kim TY, Lee KH, Hwang PG, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ., Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients, LUNG CANCER 2006 Nov;54(2):201-7.
13
Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD., Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma, CANCER RESEARCH, 2006 Aug 1;66(15):7490-501.
12
Kim TY, Bang YJ, Robertson KD., Histone deacetylase inhibitors for cancer therapy., EPIGENETICS, 2006 Jan-Mar;1(1):14-23.
11
Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK., Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib, JOURNAL OF CLINICAL ONCOLOGY, 2005 Apr 10;23(11):2493-501.
10
Choi IS, Oh DY, Kwon JH, Kim SI, Park SR, Bak JY, Kim JH, Kim DW, Kim YT, Kim TY, You CK, Kim YW, Heo DS, Bang YJ, Sung SW, Park CI, Kim NK., Paclitaxel/platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005 Jan;35(1):6-12.
9
Han SW, Hwang PG, Chung DH, Kim DW, Im SA, Kim YT, Kim TY, Heo DS, Bang YJ, Kim NK., Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa?, ZD1839) in chemotherapy-resistant non-small cell lung cancer, INTERNATIONAL JOURNAL OF CANCER, 2005 Jan 1;113(1):109-15.
8
Sun JM, Han W, Im SA, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ, Choe KJ, Kim NK., A combination of HER-2 status and the St Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma, CANCER, 2004 Dec 1;101(11):2516-22.
1
2
3
4
5
